Advertisement
Screener

Rein Therapeutics, Inc. (RNTX) Operating Leases, Rent Expense

2.8 / 5 stars · 68/120 Roast Me

Rein Therapeutics, Inc. Operating Leases, Rent Expense

Rein Therapeutics, Inc. (RNTX) reported Operating Leases, Rent Expense of $494.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.

Discontinued › Expense Statement › Operating Expenses

us-gaap:LeaseAndRentalExpense · last filed 2018-04-02

  • Rein Therapeutics, Inc. operating leases, rent expense for the quarter ending 2017-12-31 was $127.00K, a 9.48% increase year-over-year.
  • Rein Therapeutics, Inc. operating leases, rent expense for the quarter ending 2017-09-30 was $127.00K, a 19.81% increase year-over-year.
  • Rein Therapeutics, Inc. operating leases, rent expense for the quarter ending 2017-06-30 was $120.00K, a 14.29% increase year-over-year.
  • Rein Therapeutics, Inc. operating leases, rent expense for the quarter ending 2017-03-31 was $120.00K.
  • Rein Therapeutics, Inc. operating leases, rent expense for fiscal 2017 was $494.00K, a 14.35% increase from fiscal 2016.
  • Rein Therapeutics, Inc. operating leases, rent expense for fiscal 2016 was $432.00K, a 67.44% increase from fiscal 2015.
  • Rein Therapeutics, Inc. operating leases, rent expense for fiscal 2015 was $258.00K.
Period endOperating Leases, Rent Expense 3 monthOperating Leases, Rent Expense 6 monthOperating Leases, Rent Expense 9 monthOperating Leases, Rent Expense 12 month
2017-12-31$127.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02
$254.00K
derived: sum of 2 quarters · filed 2018-04-02
$374.00K
derived: sum of 3 quarters · filed 2018-04-02
$494.00K
10-K · filed 2018-04-02
2017-09-30$127.00K
10-Q · filed 2017-11-09
$247.00K
derived: sum of 2 quarters · filed 2017-11-09
$367.00K
10-Q · filed 2017-11-09
$483.00K
derived: sum of 4 quarters · filed 2018-04-02
2017-06-30$120.00K
10-Q · filed 2017-08-10
$239.00K
10-Q · filed 2017-08-10
$356.00K
derived: sum of 3 quarters · filed 2018-04-02
$462.00K
derived: sum of 4 quarters · filed 2018-04-02
2017-03-31$120.00K
derived: 10-K 12 month − 3 quarters · filed 2018-04-02
$236.00K
derived: sum of 2 quarters · filed 2018-04-02
$342.00K
derived: sum of 3 quarters · filed 2018-04-02
$447.00K
derived: sum of 4 quarters · filed 2018-04-02
2016-12-31$116.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02
$222.00K
derived: sum of 2 quarters · filed 2018-04-02
$327.00K
derived: sum of 3 quarters · filed 2018-04-02
$432.00K
10-K · filed 2018-04-02
2016-09-30$106.00K
10-Q · filed 2017-11-09
$211.00K
derived: sum of 2 quarters · filed 2017-11-09
$316.00K
10-Q · filed 2017-11-09
2016-06-30$105.00K
10-Q · filed 2017-08-10
$211.00K
10-Q · filed 2017-08-10
2015-12-31$258.00K
10-K · filed 2018-04-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
HYPERION DEFI, INC. (HYPD)United States$0.065B
XBiotech Inc. (XBIT)United States$0.066B-1.56
Skye Bioscience, Inc. (SKYE)United States$0.061B-0.48
CalciMedica, Inc. (CALC)United States$0.061B-1.42
TALPHERA, INC. (TLPH)United States$0.060B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58